Antisense-based cancer therapeutics: are we there yet?

Bibliography

• MELISI D, TROIANI T, DAMIANO V, TORTORA G, CIARDIELLO F: Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr. Relat. Cancer (2004) 11:51-68.
   PubMed Web of Science ®Google Scholar
• DE BONO JS, ROWINSKY EK: Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br. Med. Bull. (2002) 64:227-254.
   PubMed Web of Science ®Google Scholar
• ZHANG R, WANG H, AGRAWAL S: Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr. Cancer Drug Targets (2005) 5:43-49.
   PubMed Web of Science ®Google Scholar
• CHI KN, GLEAVE ME: Antisense approaches in prostate cancer. Expert Opin. Biol. Ther. (2004) 4:927-936.
   PubMed Web of Science ®Google Scholar
• GOLD DG, NEGLIA JP, DUSENBERY KE: Second neoplasms after megavoltage radiation for pediatric tumors. Cancer (2003) 97:2588-2596.
   PubMed Web of Science ®Google Scholar
• ZAMECNIK P, STEPHENSON M: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA (1978) 75:280-284.
   PubMed Web of Science ®Google Scholar
• RAYBURN ER, WANG W, ZHANG R, WANG H: Antisense approaches in drug discovery and development. Prog. Drug Res. (2005) 53:227-274.
   Google Scholar
• RAYBURN E, WANG H, HE J, ZHANG R: RNA silencing technologies in drug discovery and target validation. Letters in Drug Design and Discovery (2005) 2:1-18.
   Web of Science ®Google Scholar
• GLEAVE ME, MONIA BP: Antisense therapy for cancer. Nat. Rev. Cancer (2005) 5:468-479.
   PubMed Web of Science ®Google Scholar
• CROOKE S: Vitravene – another piece in the mosaic. Antisense Nucleic Acid Drug Dev. (1998) 8:vii-viii.
   PubMedGoogle Scholar
• RAVICHANDRAN LV, DEAN NM, MARCUSSON EG: Use of antisense oligonucleotides in functional genomics and target validation. Oligonucleotides (2004) 14:49-64.
   PubMed Web of Science ®Google Scholar
• JONES SW, LINDSAY MA: Overview of target validation and the impact of oligonucleotides. Curr. Opin. Mol. Ther. (2004) 6:546-550.
   PubMed Web of Science ®Google Scholar
• SHANKAR SL, MANI S, O’GUIN KN, KANDIMALLA ER, AGRAWAL S, SHAFIT-ZAGARDO B: Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J. Neurochem. (2001) 79:426-436.
   PubMed Web of Science ®Google Scholar
• ALTIERI DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene (2003) 22:8581-8589.
   PubMed Web of Science ®Google Scholar
• PATIL SD, RHODES DG, BURGESS DJ: DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. (2005) 8:E61-E77.
   Google Scholar
• FAR RK, LEPPERT J, FRANK K, SCZAKIEL G: Technical improvements in the computational target search for antisense oligonucleotides. Oligonucleotides (2005) 15:223-233.
   PubMed Web of Science ®Google Scholar
• BIROCCIO A, LEONETTI C, ZUPI G: The future of antisense therapy: combination with anticancer treatments. Oncogene (2003) 22:6579-6588.
   PubMed Web of Science ®Google Scholar
• KIM R, EMI M, TANABE K, TOGE T: Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer (2004) 101:2491-2502.
   PubMed Web of Science ®Google Scholar
• LENDVAI G, VELIKYAN I, BERGSTROM M et al.: Biodistribution of (68)Ga-labelled phosphodiester, phosphorothioate, and 2′-O-methyl phosphodiester oligonucleotides in normal rats. Eur. J. Pharm. Sci. (2005) 135:949-958.
   Google Scholar
• ZHENG JG, TAN TZ: Antisense imaging of colon cancer-bearing nude mice with liposome-entrapped 99m-technetium-labeled antisense oligonucleotides of c-myc mRNA. World J. Gastroenterol. (2004) 10:2563-2566.
   PubMed Web of Science ®Google Scholar
• WANG J, CHEN P, MRKOBRADA M, HU M, VALLIS KA, REILLY RM: Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts. Eur. J. Nucl. Med. Mol. Imaging (2003) 30:1273-1280.
   PubMed Web of Science ®Google Scholar
• NIMJEE SM, RUSCONI CP, SULLENGER BA: Aptamers: an emerging class of therapeutics. Ann. Rev. Med. (2005) 56:555-583.
   PubMed Web of Science ®Google Scholar
• WALDER RY, WALDER JA: Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA (1988) 85:5011-5015.
   PubMed Web of Science ®Google Scholar
• CROOKE ST: Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta (1999) 1489:31-44.
   PubMed Web of Science ®Google Scholar
• WU H, LIMA W, ZHANG H, FAN A, SUN H, CROOKE S: Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. (2004) 279:17181-17189.
   PubMed Web of Science ®Google Scholar
• KURRECK J: Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. (2003) 270:1628-1644.
   PubMedGoogle Scholar
• AGRAWAL S: Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta. (1999) 1489:53-68.
   PubMed Web of Science ®Google Scholar
• URBAN E, NOE C: Structural modifications of antisense oligonucleotides. Il Farmaco (2003) 58:243-258.
   PubMedGoogle Scholar
• DEAN N, BENNETT C: Antisense oligonucleotide-based therapeutics for cancer. Oncogene (2003) 22:9087-9096.
   PubMed Web of Science ®Google Scholar
• ZELLWEGER T, MIYAKE H, JULY L, AKBARI M, KIYAMA S, GLEAVE M: Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia (2001) 3:360-367.
   PubMed Web of Science ®Google Scholar
• BARTEL F, HARRIS L, WURL P, TAUBERT H: MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides. Mol. Cancer Res. (2004) 2:29-35.
   PubMed Web of Science ®Google Scholar
• KOLE R, WILLIAMS T, COHEN L: RNA modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim. Pol. (2004) 51:373-378.
   PubMed Web of Science ®Google Scholar
• PRAKASH TP, JOHNSTON JF, GRAHAM MJ, CONDON TP, MANOHARAN M: 2′-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo. Nucleic Acids Res. (2004) 32:828-833.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, ZHAO Q: Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. (1998) 8:135-139.
   PubMedGoogle Scholar
• ZHANG Z, LI M, WANG H, AGRAWAL S, ZHANG R: Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. USA (2003) 100:11636-11641.
   PubMed Web of Science ®Google Scholar
• PRASAD G, WANG H, AGRAWAL S, ZHANG R: Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anti-Cancer Res. (2002) 22:107-116.
   PubMed Web of Science ®Google Scholar
• RAY A, NORDEN B: Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. FASEB J. (2000) 14:1041-1060.
   PubMed Web of Science ®Google Scholar
• TAMM I: Antisense therapy in clinical oncology: preclinical and clinical experiences. Methods Mol. Med. (2005) 106:113-134.
   PubMedGoogle Scholar
• RIEDEL F, GOTTE K, LI M, HORMANN K, GRANDIS JR: Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo. Int. J. Oncol. (2003) 23:577-583.
   PubMed Web of Science ®Google Scholar
• NIWA H, WENTZEL AL, LI M, GOODING WE, LUI VW, GRANDIS JR: Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin. Cancer Res. (2003) 9:5028-5035.
   PubMed Web of Science ®Google Scholar
• LAHN M, KLOEKER S, BERRY BS: TGF-β inhibitors for the treatment of cancer. Expert Opin. Investig. Drugs. (2005) 14:629-643.
   PubMed Web of Science ®Google Scholar
• PESSION A, TONELLI R, FRONZA R et al.: Targeted inhibition of NMYC by peptide nucleic acid in N-myc amplified human neuroblastoma cells: cell-cycle inhibition with induction of neuronal cell differentiation and apoptosis. Int. J. Oncol. (2004) 24:265-272.
   PubMed Web of Science ®Google Scholar
• CUMMINGS J, WARD TH, LACASSE E et al.: Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer (2005) 92:532-538.
   PubMed Web of Science ®Google Scholar
• HOLMLUND JT: Applying antisense technology: affinitak and other antisense oligonucleotides in clinical development. Ann. NY Acad. Sci. (2003) 1002:244-251.
   PubMed Web of Science ®Google Scholar
• HAYWARD RL, MACPHERSON JS, CUMMINGS J, MONIA BP, SMYTH JF, JODRELL DI: Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol. Cancer Ther. (2004) 3:169-178.
   PubMed Web of Science ®Google Scholar
• ZHANG Z, WANG H, PRASAD G et al.: Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin. Cancer Res. (2004) 10:1263-1273.
   PubMed Web of Science ®Google Scholar
• RAIT AS, PIROLLO KF, ULICK D, CULLEN K, CHANG EH: HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann. NY Acad. Sci. (2003) 1002:78-89.
   PubMed Web of Science ®Google Scholar
• MANI S, GOEL S, NESTEROVA M et al.: Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM-231) targeted against protein kinase A type I. Ann. NY Acad. Sci. (2003) 1002:252-262.
   PubMed Web of Science ®Google Scholar
• KO YJ, DEVI GR, LONDON CA et al.: Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J. Urol. (2004) 172:1140-1144.
   PubMed Web of Science ®Google Scholar
• BIANCO R, CIARDIELLO F, TORTORA G: Chemosensitization by antisense oligonucleotides targeting MDM2. Curr. Cancer Drug Targets. (2005) 5:51-56.
   PubMed Web of Science ®Google Scholar
• BALTOGIANNIS D, CHARALABOPOULOS K, GIANNAKOPOULOS X, KARAKOSTA A, SOFIKITIS N: Combined use of antisense oligonucleotides and chemotherapeutics in the treatment of refractory prostate cancer. Exp. Oncol. (2005) 27:91-93.
   PubMed Web of Science ®Google Scholar
• ZAFFARONI N, PENNATI M, DAIDONE MG: Survivin as a target for new anticancer interventions. J. Cell. Mol. Med. (2005) 9:360-372.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, KANDIMALLA E, YU D et al.: Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides. Int. J. Oncol. (2001) 18:1061-1069.
   PubMed Web of Science ®Google Scholar
• WANG H, NAN L, YU D, AGRAWAL S, ZHANG R: Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. (2001) 7:3613-3624.
   PubMed Web of Science ®Google Scholar
• WANG H, WANG S, NAN L, YU D, AGRAWAL S, ZHANG R: Antisense anti-MDM2 mixed backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: in vivo activity and mechanisms. Intl. J. Oncol. (2002) 20:745-752.
   PubMed Web of Science ®Google Scholar
• WANG H, OLIVER P, ZHANG Z, AGRAWAL S, ZHANG R: Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann. NY Acad. Sci. (2003) 1002:217-235.
   PubMed Web of Science ®Google Scholar
• KLASA RJ: Targeting the proapoptotic factor Bcl-2 in non-Hodgkin’s lymphoma. Oncology (2004) 18:25-31.
   PubMedGoogle Scholar
• TOLCHER AW, CHI K, KUHN J et al.: A Phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. (2005) 11:3854-3861.
   PubMed Web of Science ®Google Scholar
• DAVIS AJ, GELMON KA, SIU LL et al.: Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs. (2003) 21:85-97.
   PubMed Web of Science ®Google Scholar
• OZA AM, ELIT L, SWENERTON K et al.: Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol. Oncol. (2003) 89:129-133.
   PubMed Web of Science ®Google Scholar
• TOLCHER AW, REYNO L, VENNER PM et al.: A randomized Phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. (2002) 8:2530-2535.
   PubMed Web of Science ®Google Scholar
• CRIPPS MC, FIGUEREDO AT, OZA AM et al.: Phase II randomized study of ISIS-3521 and ISIS-5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin. Cancer Res. (2002) 8:2188-2192.
   PubMed Web of Science ®Google Scholar
• RUDIN CM, MARSHALL JL, HUANG CH et al.: Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a Phase I study. Clin. Cancer Res. (2004) 10:7244-7251.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM CC, HOLMLUND JT, GEARY RS et al.: A Phase I trial of H-ras antisense oligonucleotide ISIS-2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer (2001) 92:1265-1271.
   PubMed Web of Science ®Google Scholar
• ADJEI AA, DY GK, ERLICHMAN C et al.: A Phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin. Cancer Res. (2003) 9:115-123.
   PubMed Web of Science ®Google Scholar
• ALBERTS SR, SCHROEDER M, ERLICHMAN C et al.: Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II trial. J. Clin. Oncol. (2004) 22:4944-4950.
   PubMed Web of Science ®Google Scholar
• ORR RM: Technology evaluation: leukemia therapy, University of Pennsylvania. Curr. Opin. Mol. Ther. (1999) 1:399-403.
   PubMed Web of Science ®Google Scholar
• ARORA V, CATE ML, GHOSH C, IVERSEN PL: Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab. Dispos. (2002) 30:757-762.
   PubMed Web of Science ®Google Scholar
• SARMIENTO UM, PEREZ JR, BECKER JM, NARAYANAN R: In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. (1994) 4:99-107.
   PubMedGoogle Scholar
• KRIEG AM, YI AK, MATSON S et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549.
   PubMed Web of Science ®Google Scholar
• LEVIN AA: A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta. (1999) 1489:69-84.
   PubMed Web of Science ®Google Scholar
• CHI KN, EISENHAUER E, FAZLI L et al.: A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. (2005) 97:1287-1296.
   PubMed Web of Science ®Google Scholar
• LAHN M, PATERSON BM, SUNDELL K, MA D: The role of protein kinase C-α (PKC-α) in malignancies of the gastrointestinal tract. Eur. J. Cancer. (2004) 40:10-20.
   PubMed Web of Science ®Google Scholar
• MARCUCCI G, STOCK W, DAI G et al.: Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. (2005) 23:3404-3411.
   PubMed Web of Science ®Google Scholar
• SHANKAR P, MANJUNATH N, LIEBERMAN J: The prospect of silencing disease using RNA interference. JAMA (2005) 293:1367-1373.
   PubMed Web of Science ®Google Scholar
• LYSIK M, WU-PONG S: Innovations in oligonucleotide drug delivery. J. Pharm. Sci. (2003) 92:1559-1573.
   PubMed Web of Science ®Google Scholar
• VAN OEKELEN D, LUYTEN WH, LEYSEN JE: Ten years of antisense inhibition of brain G-protein-coupled receptor function. Brain Res. Brain Res. Rev. (2003) 42:123-142.
   PubMed Web of Science ®Google Scholar
• GARCIA-CHAUMONT C, SEKSEK O, GRZYBOWSKA J, BOROWSKI E, BOLARD J: Delivery systems for antisense oligonucleotides. Pharmacol. Ther. (2000) 87:255-277.
   PubMed Web of Science ®Google Scholar
• ESCRIOU V, CARRIERE M, SCHERMAN D, WILS P: NLS bioconjugates for targeting therapeutic genes to the nucleus. Adv. Drug Deliv. Rev. (2003) 55:295-306.
   PubMed Web of Science ®Google Scholar
• ASTRIAB-FISHER A, FISHER M, JULIANO R, HERDEWIJN P: Increased uptake of antisense oligonucleotides by delivery as double stranded complexes. Biochem. Pharmacol. (2004) 68:403-407.
   PubMed Web of Science ®Google Scholar
• LI Z, ZHU S, GAN K et al.: Poly-l-lysine-modified silica nanoparticles: a potential oral gene delivery system. J. Nanosci. Nanotechnol. (2005) 5:1199-1203.
   PubMed Web of Science ®Google Scholar
• LOCHMANN D, WEYERMANN J, GEORGENS C, PRASSL R, ZIMMER A: Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization. Eur. J. Pharm. Biopharm. (2005) 59:419-429.
   PubMed Web of Science ®Google Scholar
• WEYERMANN J, LOCHMANN D, GEORGENS C, ZIMMER A: Albumin-protamine-oligonucleotide- nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect. Eur. J. Pharm. Biopharm. (2005) 59:431-438.
   PubMed Web of Science ®Google Scholar
• PASTORINO F, BRIGNOLE C, MARIMPIETRI D et al.: Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications. Ann. NY Acad. Sci. (2004) 1028:90-103.
   PubMed Web of Science ®Google Scholar
• BRIGNOLE C, MARIMPIETRI D, PAGNAN G et al.: Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD(2) immunoliposome: immune cell-mediated anti-tumor activities. Cancer Lett. (2005) 228:181-186.
   PubMed Web of Science ®Google Scholar
• SPRINGATE CM, JACKSON JK, GLEAVE ME, BURT HM: Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemother. Pharmacol. (2005) 56:239-247.
   PubMed Web of Science ®Google Scholar
• KIPSHIDZE NN, PORTER TR, DANGAS G et al.: Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovasc. Radiat. Med. (2003) 4:152-159.
   PubMedGoogle Scholar
• ZHANG XX, CUI CC, XU XG, HU XS, FANG WH, KUANG BJ: In vivo distribution of c-myc antisense oligodeoxynucleotides local delivered by gelatin-coated platinum-iridium stents in rabbits and its effect on apoptosis. Chin. Med. J. (Engl.) (2004) 117:258-263.
   PubMed Web of Science ®Google Scholar
• ROTH C, SUNDARAM S: Engineering synthetic vectors for improved DNA delivery: insights from intracellular pathways. Ann. Rev. Biomed. Eng. (2004) 6:397-426.
   PubMed Web of Science ®Google Scholar
• ZHANG S, XU Y, WANG B, QIAO W, LIU D, LI Z: Cationic compounds used in lipoplexes and polyplexes for gene delivery. J. Control. Release (2004) 100:165-180.
   PubMed Web of Science ®Google Scholar
• ZHAO Q, TEMSAMANI J, IADAROLA PL, AGRAWAL S: Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochem. Pharmacol. (1996) 52:1537-1544.
   PubMed Web of Science ®Google Scholar
• WEBB M, TORTORA N, CREMESE M et al.: Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. (2001) 11:155-163.
   PubMedGoogle Scholar
• AGRAWAL S, ZHAO Q, JIANG Z, OLIVER C, GILES H, HEATH J, SEROTA D: Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev. (1997) 7:575-584.
   PubMedGoogle Scholar
• HENRY S, ZUCKERMAN J, ROJKO J et al.: Toxicological properties of several novel oligonucleotide analogs in mice. Anti-Cancer Drug Des. (1997) 12:1-14.
   PubMedGoogle Scholar
• JASON TL, KOROPATNICK J, BERG RW: Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. (2004) 201:66-83.
   PubMed Web of Science ®Google Scholar
• KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. (2002) 20:709-760.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, IADAROLA P, TEMSAMANI J, ZHAO Q, SHAW D: Effect of G-rich sequences on the synthesis, purification, binding, cell uptake, and hemolytic activity of oligonucleotides. Bioorg. Med. Chem. Lett. (1996) 6:2219-2224.
   Web of Science ®Google Scholar
• LAI JC, BENIMETSKAYA L, SANTELLA RM, WANG Q, MILLER PS, STEIN CA: G-3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol. Cancer Ther. (2003) 2:1031-1043.
   PubMed Web of Science ®Google Scholar
• RAOOF AA, CHIU P, RAMTOOLA Z et al.: Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J. Pharm. Sci. (2004) 93:1431-1439.
   PubMed Web of Science ®Google Scholar
• WANG H, RAYBURN E, ZHANG R: Synthetic oligodeoxynucleotides containing deoxycitidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogues as novel anticancer therapeutics. Curr. Pharm. Des. (2005) 11:2889-2907.
   PubMed Web of Science ®Google Scholar
• WOOLDRIDGE JE, WEINER GJ: CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr. Opin. Oncol. (2003) 15:440-445.
   PubMedGoogle Scholar
• LONG MB, JONES JP 3rd, SULLENGER BA, BYUN J: Ribozyme-mediated revision of RNA and DNA. J. Clin. Invest. (2003) 112:312-318.
   PubMed Web of Science ®Google Scholar
• ROGERS CS, VANOYE CG, SULLENGER BA, GEORGE AL JR: Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J. Clin. Invest. (2002) 110:1783-1789.
   PubMed Web of Science ®Google Scholar
• CITTI L, RAINALDI G: Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr. Gene Ther. (2005) 5:11-24.
   PubMed Web of Science ®Google Scholar
• SONTHEIMER EJ: Assembly and function of RNA silencing complexes. Nat. Rev. Mol. Cell Biol. (2005) 6:127-138.
   PubMed Web of Science ®Google Scholar
• SILVA J, CHANG K, HANNON GJ, RIVAS FV: RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age. Oncogene (2004) 23:8401-8409.
   PubMed Web of Science ®Google Scholar
• BERTRAND JR, POTTIER M, VEKRIS A, OPOLON P, MAKSIMENKO A, MALVY C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. (2002) 296:1000-1004.
   PubMed Web of Science ®Google Scholar